<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01169649</url>
  </required_header>
  <id_info>
    <org_study_id>10-067</org_study_id>
    <nct_id>NCT01169649</nct_id>
  </id_info>
  <brief_title>Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)</brief_title>
  <official_title>A Phase II Clinical and Translational Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test a new drug called MK-2206. This study is a phase II&#xD;
      study. In cancer studies, a phase II study is to find out what effects, good and/or bad, a&#xD;
      new treatment has against a certain type of cancer.&#xD;
&#xD;
      MK-2206 is an oral medication known as a targeted therapy. By attaching to the target, we&#xD;
      hope that MK-2206 may stop the cancer cells from further growth and dividing. This study will&#xD;
      help find out if MK-2206 is a helpful drug when taken in patients with neuroendocrine tumor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response.</measure>
    <time_frame>every 12 weeks</time_frame>
    <description>Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>PANCREAS</condition>
  <condition>Neuroendocrine</condition>
  <arm_group>
    <arm_group_label>islet cell carcinomas and carcinoid tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-2206</intervention_name>
    <description>MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.</description>
    <arm_group_label>islet cell carcinomas and carcinoid tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed moderately to well&#xD;
             differentiated metastatic or unresectable carcinoid or islet cell tumors.&#xD;
&#xD;
          -  Patient has at least one measurable lesion greater than or equal to 20 mm on CT or MRI&#xD;
             imaging.&#xD;
&#xD;
          -  Patients who are on therapy with a somatostatin analog are eligible for entry but must&#xD;
             be on a stable dose for at least 3 months with no evidence of tumor shrinkage during&#xD;
             that time period.&#xD;
&#xD;
          -  Patient ≥18 years of age on the day of signing informed consent.&#xD;
&#xD;
          -  Patient has performance status 0-1 on the ECOG Performance Scale.&#xD;
&#xD;
          -  Patient has adequate organ function as indicated by the following laboratory values:&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC)≥1,500/mcL&#xD;
&#xD;
          -  Platelets ≥100,000/mcL&#xD;
&#xD;
          -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
          -  Serum Creatinine ≤2 times the upper limit of normal (ULN)/ OR calculated CrCl ≥60&#xD;
             mL/min (patients with creatinine levels ≥2 times the ULN only). Patient may not be on&#xD;
             dialysis&#xD;
&#xD;
          -  Serum total bilirubin ≤1.5 times the ULN&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) ≤5 times the ULN&#xD;
&#xD;
          -  HgbA1c ≤ 8%&#xD;
&#xD;
          -  Fasting Glucose ≤120 mg/dl&#xD;
&#xD;
          -  Creatinine clearance should be calculated by the Cockcroft-Gault method.Fasting is&#xD;
             defined as at least 4 hours without oral intake.&#xD;
&#xD;
          -  Patient has voluntarily agreed to participate by giving written informed consent.&#xD;
&#xD;
          -  Previous local therapy (e.g. chemoembolization or bland embolization) is allowed if&#xD;
             completed &gt; 6 weeks or 5X half-life prior to study entry. For patients who received&#xD;
             local therapy prior to study entry, there must be either documented growth of&#xD;
             measurable disease within the embolization field or outside of the embolization field,&#xD;
             or both, prior to study entry if the area of the embolization field was the only site&#xD;
             of measurable disease.&#xD;
&#xD;
          -  Previous chemotherapy, radiotherapy, and/or biologic therapy, including&#xD;
             investigational agents, is/are allowed if completed &gt; 4 weeks prior to study entry (&gt;6&#xD;
             weeks if last regimen contained bevacizumab, BCNU or mitomycin C, and &gt; 6 weeks from&#xD;
             last dose of radiation therapy or radiopharmaceutical.&#xD;
&#xD;
          -  Patients must not have disease that is currently amenable to curative surgery. Prior&#xD;
             surgery is allowed no less than 6 weeks prior to study entry.&#xD;
&#xD;
          -  Patients with diabetes mellitus are eligible for study entry but must have controlled&#xD;
             diabetes as defined by hemoglobin A1c &lt;8.0% within 2 weeks of initiation of protocol&#xD;
             therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has toxicities from prior therapies that have not resolved to grade 1 or grade&#xD;
             0.&#xD;
&#xD;
          -  Patient has known active CNS metastases and/or carcinomatous meningitis are excluded.&#xD;
             However, patients with CNS metastases who have completed a course of therapy would be&#xD;
             eligible for the study provided they are clinically stable for 1 month prior to entry&#xD;
             as defined as: (1) no evidence of new or enlarging CNS metastasis (2) off steroids&#xD;
             that are used to minimize surrounding brain edema.&#xD;
&#xD;
          -  Patient has an active malignancy of metastatic potential other than the known&#xD;
             carcinoid or islet cell tumor, for the past 3 years.&#xD;
&#xD;
          -  Patient has a known hypersensitivity to the components of study drug (MK-2206) or its&#xD;
             analogs that is not treatable by premedication with antihistamines and steroids.&#xD;
&#xD;
          -  Patient has a condition, including but not limited to&#xD;
&#xD;
          -  symptomatic congestive heart failure&#xD;
&#xD;
          -  unstable angina pectoris&#xD;
&#xD;
          -  serious cardiac arrhythmia&#xD;
&#xD;
          -  history or current evidence of a myocardial infarction during the last 6 months,&#xD;
             and/or a current ECG tracing that is abnormal in the opinion of the treating&#xD;
             investigator&#xD;
&#xD;
          -  QTc prolongation &gt;450 msec (Bazett's formula)&#xD;
&#xD;
          -  Patient with evidence of clinically significant bradycardia (HR &lt;50), or a history of&#xD;
             clinically significant bradyarrhythmias such as sick sinus syndrome, 2nd degree AV&#xD;
             block (Mobitz Type 2).&#xD;
&#xD;
          -  Patient with uncontrolled hypertension (i.e., 160/90 mHg SiBP). Patients who are&#xD;
             controlled on antihypertensive medication will be allowed to enter the study.&#xD;
&#xD;
          -  Patient at significant risk for hypokalemia (e.g., patients on high dose diuretics, or&#xD;
             with recurrent diarrhea)&#xD;
&#xD;
          -  Patient is a known diabetic who is poorly controlled (HBAc&gt;8%)&#xD;
&#xD;
          -  Patient has a history or current evidence of any condition, therapy, or lab&#xD;
             abnormality that might confound the results of the study, interfere with the patient's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the patient to participate, in the opinion of the treating Investigator.&#xD;
&#xD;
          -  Patient has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
          -  Patient is, at the time of signing informed consent, a regular user (including&#xD;
             -recreational use‖) of any illicit drugs or had a recent history (within the last&#xD;
             year) of drug or alcohol abuse.&#xD;
&#xD;
          -  Patient is pregnant or breastfeeding, or expecting to conceive or father children&#xD;
             within the projected duration of the study.&#xD;
&#xD;
          -  Patient is known to be Human Immunodeficiency Virus (HIV)-positive&#xD;
&#xD;
          -  Patient has known history of Hepatitis C or active Hepatitis A or B.&#xD;
&#xD;
          -  Patient has symptomatic ascites or pleural effusion. A patient who is clinically&#xD;
             stable following treatment for these conditions is eligible.&#xD;
&#xD;
          -  Patient has prior treatment with an mTOR inhibitor such as afinitor, sirolimus, or&#xD;
             temsirolimus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane Reidy-Lagunes, MD,MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>July 21, 2010</study_first_submitted>
  <study_first_submitted_qc>July 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2010</study_first_posted>
  <results_first_submitted>April 8, 2015</results_first_submitted>
  <results_first_submitted_qc>January 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 18, 2016</results_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MK-2206</keyword>
  <keyword>Neuroendocrine Tumors</keyword>
  <keyword>10-067</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK-2206 in Patients With Metastatic Neuroendocrine Tumors</title>
          <description>This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-2206 in Patients With Metastatic Neuroendocrine Tumors</title>
          <description>This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response.</title>
        <description>Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.</description>
        <time_frame>every 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MK-2206 in Patients With Metastatic Neuroendocrine Tumors</title>
            <description>This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response.</title>
          <description>Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression of Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MK-2206 in Patients With Metastatic Neuroendocrine Tumors</title>
          <description>This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTC-4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Diane Reidy-Lagunes</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4185</phone>
      <email>reidyd@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

